• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Few clinical drug trials exist for pediatric neuropsychiatric conditions

bys25qthea
May 6, 2013
in Chronic Disease, Pediatrics, Psychiatry, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Only 10% of clinical neuropsychiatric drug trials from 2006 to 2011 were pediatric trials. 

2. Drug trials for depression (6%) and schizophrenia (6%) made up the smallest proportion of pediatric neuropsychiatric trials. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: There has been an increasing prevalence of neuropsychiatric disease among the pediatric population, which now reaches nearly 20%. However, there remain few clinical drug trials for pediatric depression, bipolar disorder, schizophrenia, migraine, and epilepsy. Children are often treated with unlicensed medications with known efficacy in adults, but without pediatric-specific guidelines. Only 10% of clinical drug trials between 2006 and 2011 for these conditions are pediatric trials. Furthermore, schizophrenia and depression, which represent the largest neuropsychiatric disease burden in youth, had the fewest drug trials devoted to them. One possible limitation is that the ClinicalTrials.gov registry, used for data collection, may not have included all relevant trials. Also, missing data and lack of verification of information provided in the registry could have contributed to errors. Nonetheless, this study points to the need for more clinical drug trials to guide safe and effective treatment for neuropsychiatric conditions in children.

Click to read the study published today in Pediatrics

Relevant Reading: Pediatric Psychopharmacology

RELATED REPORTS

The Scan by 2 Minute Medicine®: The Fight Against Childhood Obesity, Prioritizing Mental Health, The Rise of XBB1.5, and Choose Your Chocolates Wisely

Physical activity may be helpful in treating depressive symptoms in children and adolescents

ECT may be more effective than ketamine in improving depression severity

In-Depth [retrospective review study]: A total of 1046 clinical drug trials on pediatric and adult drug treatments for neuropsychiatric conditions were included. Only 10% (108/1046) of all neuropsychiatric drug trials were pediatric. Furthermore, the fewest drug trials existed for pediatric depression and schizophrenia (6% each, 17/308 and 16/290, respectively). Antiepileptics were most commonly studied drugs in children (51%, 25/49). Most (90%, 273/303) of the drugs studied were not FDA-approved for pediatric use. In addition, only 19% (47/303; 95% CI: 15-23%) of all neuropsychiatric drugs were being studied for pediatric use, in comparison with the 95% (288/303; 95% CI: 93-975) for adult use. The majority (76%, 74/97) of pediatric trials sought to expand drug use labeling from adult to pediatric age groups, while 32% (95% CI: 29-35%) of adult trials were investigating new drugs. Moreover, 26% (25/97; 95% CI: 17-35%) of pediatric trials evaluated a drug for a new indication, as compared to 42% (95% CI 38-46%) of adult trials.

By Cordelia Y. Ross and Devika Bhushan

More from this author: Many children with cancer exposed to home medication errors; Parents feeding control practices related to child’s weight and gender; Social networks play key roles in parental vaccination decisions; Shorter sleep duration associated with increased adolescent BMI; Varicella vaccine provides 14-year protection against childhood chicken pox  

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Tags: depressionneuropsychiatric drug trialsschizophreniatrials
Previous Post

Breast implants linked with later stage breast cancer, mortality

Next Post

Influenza vaccine safe for IBD patients

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Fight Against Childhood Obesity, Prioritizing Mental Health, The Rise of XBB1.5, and Choose Your Chocolates Wisely

January 25, 2023
Certain financial incentive programs may promote increased physical activity
Chronic Disease

Physical activity may be helpful in treating depressive symptoms in children and adolescents

January 18, 2023
Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse
Psychiatry

ECT may be more effective than ketamine in improving depression severity

January 18, 2023
Children’s hospital visits for suicide ideation and attempts are increasing
Psychiatry

Loneliness is associated with new onset mental health problems

January 13, 2023
Next Post
Influenza vaccine safe for IBD patients

Influenza vaccine safe for IBD patients

Immunotherapy shows efficacy for pediatric allergic asthma and rhinitis

Immunotherapy shows efficacy for pediatric allergic asthma and rhinitis

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options